+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

p53 and matrix metalloproteinases in rheumatoid arthritis: tip of an angiogenic iceberg?



p53 and matrix metalloproteinases in rheumatoid arthritis: tip of an angiogenic iceberg?



Seminars in Arthritis and Rheumatism 31(5): 287-288




(PDF emailed within 0-6 h: $19.90)

Accession: 035451433

Download citation: RISBibTeXText

PMID: 11965592

DOI: 10.1053/sarh.2002.31723


Related references

Usefulness of examinations of serum levels of matrix metalloproteinases 1, MMP-3, MMP-9, tissue inhibitor of metalloproteinases 1, hyaluronic acid and antibodies against cyclic citrullinated peptide in Lyme arthritis, rheumatoid arthritis and patients with arthritic complaints. Przeglad Epidemiologiczny 62 Suppl 1: 20-29, 2012

Usefulness of examinations of serum levels of matrix metalloproteinases 1, MMP-3, MMP-9, tissue inhibitor of metalloproteinases 1, hialuronic acid and antibodies against cyclic citrullinated peptide in Lyme arthritis, rheumatoid arthritis and patients with arthritic complaints. Przeglad Epidemiologiczny: Supplement 1, 20-29, 2008

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathogenesis of rheumatoid arthritis. Polski Merkuriusz Lekarski 20(116): 228-231, 2006

Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. Journal of Rheumatology 33(8): 1523-1529, 2006

Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis. Journal of Rheumatology 26(1): 34-40, 1999

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Annals of the Rheumatic Diseases 59(6): 455-461, 2000

Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. Journal of Rheumatology 31(2): 238-242, 2004

Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis. Arthritis and Rheumatism 44(8): 1754-1760, 2001

Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers. Rheumatology International 35(4): 749-755, 2016

Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Thyroid 12(8): 655-662, 2002

Expression of extracellular matrix metalloproteinase inducer and enhancement of the production of matrix metalloproteinases in rheumatoid arthritis. Arthritis and Rheumatism 46(2): 373-378, 2002

Matrix metalloproteinases and cartilage matrix degradation in rheumatoid arthritis. Clinical Calcium 17(4): 500-508, 2007

Matrix metalloproteinases 2 and 9 in canine rheumatoid arthritis. Veterinary Record 143(8): 219-223, 1998

Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. Journal of Rheumatology 26(2): 251-258, 1999

Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rheumatology 40(9): 988-994, 2001